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Background: Clinically useful biomarkers for patient stratification and monitoring of disease progression and drug
response are in big demand in drug development and for addressing potential safety concerns. Many diseases
influence the frequency and phenotype of cells found in the peripheral blood and the transcriptome of blood cells.
Changes in cell type composition influence whole blood gene expression analysis results and thus the discovery of
true transcript level changes remains a challenge. We propose a robust and reproducible procedure, which includes
whole transcriptome gene expression profiling of major subsets of immune cell cells directly sorted from whole
blood.
Methods: Target cells were enriched using magnetic microbeads and an autoMACS® Pro Separator (Miltenyi
Biotec). Flow cytometric analysis for purity was performed before and after magnetic cell sorting. Total RNA was
hybridized on HGU133 Plus 2.0 expression microarrays (Affymetrix, USA). CEL files signal intensity values were
condensed using RMA and a custom CDF file (EntrezGene-based).
Results: Positive selection by use of MACS® Technology coupled to transcriptomics was assessed for eight different
peripheral blood cell types, CD14+ monocytes, CD3+, CD4+, or CD8+ T cells, CD15+ granulocytes, CD19+ B cells,
CD56+ NK cells, and CD45+ pan leukocytes. RNA quality from enriched cells was above a RIN of eight. GeneChip
analysis confirmed cell type specific transcriptome profiles. Storing whole blood collected in an EDTA Vacutainer®
tube at 4°C followed by MACS does not activate sorted cells. Gene expression analysis supports cell enrichment
measurements by MACS.
Conclusions: The proposed workflow generates reproducible cell-type specific transcriptome data which can be
translated to clinical settings and used to identify clinically relevant gene expression biomarkers from whole blood
samples. This procedure enables the integration of transcriptomics of relevant immune cell subsets sorted directly
from whole blood in clinical trial protocols.
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There is an ever-increasing demand for the discovery,
validation, and application of clinically useful molecular
biomarkers that enable patient stratification, diagnosis,
monitoring of disease progression, or a better understanding
of drug response (safety and efficacy) [1-3]. Gene expression
biomarkers have been investigated in various diseases such
as autoimmune diseases [4,5], cancer [6-8], neurological
diseases [9,10], infections [11,12] and in transplantation
[13,14]. Whole blood or peripheral mononuclear cells
(PBMCs) have long been the preferred surrogate tissues
for clinical transcriptomics in biomarker research for two
major reasons: Firstly, blood is an easily accessible human
tissue, and secondly, robust sampling methods of whole
blood (e.g. PAXgene Blood RNA Tubes) [11,12,15-17] and
PBMCs [18,19] are well established. As is the case with any
tissue sample with mixed cell population, whole blood or
PBMC transcriptome analysis approaches are sensitive to
not only to variation in cell-type composition of the sample,
but also to the physiological state of the donor, and tech-
nical factors such as sample storage [20,21]. It is therefore
important to understand these factors and consider them
prior to the study.
Gene expression analysis of isolated cell populations
instead of whole blood or PBMC circumvents the need
to adjust for potential cell composition variation. Cell
populations need to be sorted from the mixture of
blood cells by means of a complex cell sorting technol-
ogy, which would need to be translated to clinical trial
settings. The decoupling process needs to guarantee
the quality of the source of the cells from limited ac-
cess to sophisticated cell sorting equipment. Variation
in the duration of transport to central laboratories
needs to be considered by ensuring sample stability and
proper storage conditions. Only a high level of reprodu-
cibility assures comparability and reliability of analysis
results within a set of samples from a patient and within
patient groups.
We assessed a cell separation technology using antibody-
coated paramagnetic beads for sorting cells directly from
human whole blood under conditions representing a
clinical trial. Positive cell selection protocols based on
Miltenyi Biotec’s whole blood microbeads were considered
for the following reasons: 1) Miltenyi Biotec’s autoMACS
Pro Separator is capable of sorting approximately 106 cells
per second in a rapid, semi-automated fashion [22]. Rapid
throughput minimizes the potential perturbation of the
transcriptome. The time required for preparative sorting
for transcriptomics analyses is sample dependent. 2) As
Lyons et al. reported, the cell purity after positive selection
is higher than that after negative selection [23]. 3) Magnetic
cell sorting can be performed in a multiplex format, thus
further decreasing sorting time when a number of cell types
are being purified.Three major components were included in the experi-
mental study design (Figure 1). One component addressed
whole transcriptome analysis of a panel of eight different
cell populations isolated directly from 6 mL whole blood,
each, collected into EDTA containing tubes using a positive
selection with the autoMACS Pro Separator, and of PBMCs
prepared from BD CPT (Becton Dickinson Cell Preparation
Tubes). EDTA, ethylendiaminetetraacetic acid, is a chelat-
ing molecule, capable of binding bivalent metal ions such
as Ca2+, Fe2+ and Mg2+. As Mg2+ ions are important co-
factors for RNA-degrading RNAses, the addition of EDTA
provides a greater RNA stability. The purified cells, repre-
senting eight different abundant blood cell populations
(CD14+ monocytes, CD3+, CD4+, or CD8+ T cells, CD15+
granulocytes, CD19+ B cells, CD56+ natural killer (NK)
cells, CD45+ pan leukocytes) are well suited for further
transcriptome analysis. Another variable considered in this
study included the evaluation of different RNA stabilization
and preservation methods in order to uncouple the site of
blood draw from the actual cell sorting process. A volume
of 6 mL was chosen, as this is a volume that can realistically
be obtained in clinical trials without exceeding the possible
total amount of blood that can be drawn in the context of
other measurements. In yet another component, we
performed clinical hematology counts and pre- and
post-sorting flow cytometric analysis of the sorted cell
populations to measure the clinical relevance and efficiency
of the experimental sampling conditions.
Here we present the results of a feasibility study and
discuss the possibilities and limitations of gene expres-
sion analysis of sorted cells in future clinical studies.
Methods
Study subjects and blood samples
Blood samples were obtained prospectively from 45 adult,
consented Caucasians (18 females and 27 males) from a
donor pool of healthy volunteers. Venous blood samples
were drawn from the cubital region using evacuated tubes
containing K2-EDTA as anticoagulant (BD™ Vacutainer,
Becton Dickinson, Franklin Lakes, New Jersey, USA)
or as control samples into PAXgene® Blood RNA Tubes
(Qiagen, Hilden, Germany).
Samples from a subset of 23 donors (10 females and
13 males) were used for hematology and flow cytome-
try evaluation. Those were the only samples used for
cell sorting.
Hematology
Blood samples were stored at 4°C for up to 6 hours
after venipuncture until analysis on a Siemens ADVIA
120 analyzer (Siemens Healthcare Diagnostics, Erlangen,
Germany). The analyzer was calibrated and controlled
according to the manufacturer’s user manual. Only
original reagents produced by the manufacturer were
Figure 1 Experimental study design. The study design consisted of three major components: (1), in blue: gene expression analysis of a panel
of eight different cell types positive selected by MACS directly from whole blood followed by GeneChip expression arrays. (2), in green: RNA
stability tests and RNA preservation methods, and (3), in yellow: hematology and pre- and post-sorting FACS analysis as controls
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ommended intervals.
Magnetic MicroBead-based cell sorting
Magnetic cell separation by MACS® Technology is based
on small superparamagnetic microbeads that are bound
to a highly specific antibody against a particular cell marker,
thus allowing for magnetic labeling of individual cell types.
Separation occurs in a MACS Column which induces a
high-gradient magnetic field (~0.6 Tesla) when placed in a
MACS Separator.
Cell separation directly from whole blood was performed
using the respective Whole Blood MicroBeads (Miltenyi
Biotec) as recommended by the manufacturer. A more
detailed description of the experimental procedure can be
found in the Additional file 1: Supplementary material.
Flow cytometry
Whole blood samples and corresponding sorted cells
were stored at 4°C until analysis on a MACSQuant® Flow
Cytometer (Miltenyi Biotec GmbH).
Anti-human monoclonal antibodies against CD3+
T-lymphocytes, CD4+ helper T-cells, CD8+ cytotoxic
T-cells, CD14+ monocytes, CD15+ granulocytes, CD19+
B-lymphocytes, CD45+ leukocytes and CD56+ NK cells
were obtained from Miltenyi Biotec GmbH. For flow cy-
tometry 250 μL suspensions of isolated cells were incubated
with 10 μL of corresponding antibodies for 10 minutes at2-8°C in the dark. The cells were washed and re-suspended
in 500 μL analysis buffer and afterwards immediately
analyzed on a MACSQuant Flow Cytometer using
MACSQuantify™ Software. Data were further processed
with FlowJo® software (www.flowjo.com).Total RNA extraction
The total RNA from the sorted and lysed cells was isolated
with the RNeasy Mini Kit (Qiagen, Hilden, Germany)
and from whole blood with the PAXgene Blood RNA
Kit (Qiagen, Hilden, Germany) according to the manufac-
turer’s recommendations. A more detailed description can
be found in the in the Additional file 1: Supplementary
material.Whole transcriptome analysis
Whole transcriptome analysis was conducted essentially as
described by Lockhart et al. [24] on expression microarrays.
The human genome U133 plus 2.0 array (Affymetrix, Inc.)
was used. GeneChip arrays were scanned using a GS 3000
scanner (Affymetrix, Inc.).
Experiments were conducted as recommended by the
manufacturer (GeneChip® Expression Analysis Technical
Manual) using the cRNA labeling, GeneChip® hybridization,
wash, and stain protocols (Affymetrix, Inc., Santa Clara,
CA, U.S.A.). Quality control was performed by visual in-
spection and expert judgment. The primary raw data
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numerical signal values.
Data analysis/Bioinformatics analysis
All gene expression analyses were performed in Partek®
Genomics Suite™, version 6.6 (www.Partek.com).
Affymetrix .cel files were RMA background corrected,
subjected to quantile normalization and scaled to a
mean of 150. A custom Entrez gene-based CDF file
was used for probe set condensation and annotation
(http://brainarray.mbni.med.umich.edu/Brainarray/Database/
CustomCDF/genomic_curated_CDF.asp). Cell type-specific
gene signatures included those genes with a signal intensity
of 200 or more in at least all but one sample of one cell type,
but less than 100 in at least all but one of the samples of the
other cell types excluding stabilized whole blood. The gene
expression databases BioGPS (http://www.BioGPS.org) and
Genevestigator (http://www.Genevestigator.com) were con-
sulted for confirmation of cell type specific gene expression
data. Gene groups for the perturbation score analysis
were downloaded from www.SABiosciences.com. Unigene
identifiers were mapped to Entrez identifiers, resulting in
502 probes of the custom, Entrezgene-based CDF file
(Additional file 2: Supplementary table). Graphical presen-




Blood samples of a subset of subjects (10 females, 13 males)
were analyzed on a Siemens ADVIA 120 analyzer (Siemens
Healthcare Diagnostics, Erlangen, Germany). Time lag
between venipuncture and analysis is considered not
to affect cell counts [25,26]. All cell counts were within
the expected range for female and male healthy volun-
teers without overt pathological conditions affecting
blood cell composition (www.Siemens.com/diagnostics)
(Additional file 1: Table S2).
Cell sorting experiments - total RNA yield and quality
Total RNA yield and quality were assessed for stabilized
whole blood samples and for isolated cell populations. Cell
separation from K2-EDTA anticoagulated whole blood sam-
ples started within 30 minutes after venipuncture.
Overall, the total RNA yields and quality were suffi-
cient for all different cell types tested (Additional file 1:
Figure S1). The highest mean RIN value was 9.65 ± 0.18
for CD14+ cells, the lowest was 8.62 ± 0.65 for stabilized
whole blood. The lowest RIN value was 6.6 for one of
58 whole blood samples. All total RNA samples were
processed further in Affymetrix DNA microarray ex-
periments. The mean quantity of extracted RNA per
6 mL ranged from 0.35 ± 0.12 μg for CD56+ cells to
9.8 ± 5.12 μg for whole blood. The minimum amountof extracted total RNA was 0.113 μg, the maximum
was 24.6 μg for a CD15+ samples and a blood sample,
respectively.
Cell sorting experiments - total RNA stability
To address the influence of potentially stabilizing additives
in blood collection tubes on the stability of the extracted
RNA over time, an EDTA-based additive was compared to
formaldehyde-based additives from two vendors, A and B.
The collection tube with formaldehyde-based additive
from vendor A is designed for stabilizing white blood
cells for FACS analysis [27-31], the tube-type from
vendor B is designed for stabilizing circulating tumor
cells [25,26,32]. Whole blood was drawn and kept for
up to 7 days at 4°C in the case of the EDTA-based tubes,
and at either ambient temperature or at 4°C in the case of
the formaldehyde-based tubes. CD14+ cells were isolated
and total RNA was extracted. As shown in Figure 2A,
RNA integrity decreased at ambient temperature over
time for each formulation. The EDTA-based formulation,
for which only a storage temperature of 4°C was tested,
was superior to the formaldehyde-based formulations and
yielded the best stability data even after 7 days at 4°C, as
indicated by consistent RIN values above 8, which stayed
almost unchanged from the RIN value obtained with
immediate processing. The following experiments were
conducted with EDTA-based formulation tubes.
The total RNA integrity of all other isolated cell types
could be preserved, when stored at 4°C for up to 7 days
in an EDTA-based additive (Figure 2B). The RIN value
remained consistent for total RNA of CD19+ and CD14+
cells, but decreased slightly for CD8+ and CD15+ cells
whilst remaining at a value, which is still acceptable for
gene expression experiments. While the RNA integrity
remained at a high level over a period of 7 days, the RNA
yield decreased, as shown in Figure 2C. CD4+ and CD14+
cell preparations gave the highest total RNA yields,
CD19+ and CD15+ the lowest.
Experimental procedures do not activate cells
Gene expression data from sorted cells may be informative
of the health status of a patient. To avoid any distortion of
the information on a patient’, it is important to ensure that
the experimental procedure of blood sampling at a health
center, storage and/or transport, cell sorting, and RNA ex-
traction does not affect the activation state of the immune
cells in a sample. An experiment was designed to address
this question. The results are shown in Figure 3A. An
aliquot of 2.5 mL whole blood was collected directly into
PAXgene Blood RNA Tubes containing RNA-stabilizing
solution (“PAXgene, Time 0”, experimental group 1).
To simulate a sample transport from the bedside to the
laboratory, another 2.5 mL aliquot of whole blood was
collected into EDTA-tubes, stored for 20 minutes without
Figure 2 RNA integrity and yield over time. (A) The influence of formaldehyde (HCHO)-based and EDTA-based additives on RNA integrity,
when whole blood was stored at ambient temperature or at 4°C for up to 7 days prior to sorting. EDTA-admixtures resulted in constantly high
RIN values for the cell preparations up to 7 days of storage at 4°C. (B) All five tested cell types (N = 5 each) showed a good total RNA quality
when stored in the EDTA blood collection tubes at 4°C for up to 7 days prior to sorting. (C) Total RNA extraction for all five tested cell types
(N = 5 each) resulted in total RNA amounts sufficient for further downstream experiments even when stored in the EDTA blood collection tubes
at 4°C for up to 7 days. In all panels, mean values per group and the standard error of mean are shown.
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Figure 3 Cells are not activated by experimental procedure. (A) Four experimental groups (EG) were designed to test whether whole blood
cells are activated at time of blood draw and transfer to PAXgene Blood RNA tubes (EG 1), and after storage of blood in EDTA tubes for 20 minutes prior
to transfer to PAXgene Blood RNA tubes (EG2). Additionally, whole blood cells, which had been exposed to EDTA, were incubated with CD14ab-coated
magnetic beads (EG3) or without magnetic beads (EG4). The perturbation score is nearly constant for all conditions, indicating a lack of activation. Mean
values per group and the standard error of mean are shown. (B) Separated cells were stored in EDTA for up to 7 days prior to sorting. The perturbation
score level is different for each cell type, but does not change significantly per cell type, indicating that cells are not activated during the experiment
including the sorting process. Mean values per group and the standard error of mean are shown. (C) Perturbation score analysis for CD14+ cells which
had been stored in EDTA as room temperature (RT). The score increases after 4 hours storage time. The experiment was discontinued after 24 hours.
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RNA Tube (“PAXgene, Time 1”, experimental group 2).
To test the influence of the cell sorting procedure on theactivation state of the cells (exemplified on CD14+ cells),
2.5 mL aliquots of whole blood stored in EDTA for
20 minutes were exposed to magnetic beads coated with
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(“PAXgene 3”, “PAXgene 4”, experimental group 3 and 4,
respectively). Following the incubation, the whole blood
aliquots were transferred to PAXgene Blood RNA Tubes.
Total RNA was extracted from all samples. This ex-
perimental design simulates the steps from blood draw
(experimental group 1) to the laboratories and the effect of
storage in EDTA tubes (experimental group 2), the effect of
experimental procedures (experimental group 3) and the
effect of antibody-coated beads (experimental group 4). To
test the activation state of the cells, we selected transcript
groups representative of cellular stress response, apoptosis,
cell cycle, and hypoxia including genes of the MAPK path-
way, Nfkb pathway, and TNF pathway (Additional file 2:






per sample, where I is the
signal intensity per transcript (over all n = 503 transcripts in
the combined groups defined above). The perturbation
score for whole blood RNA was unchanged in all four con-
ditions, indicating that the cells were not activated during
the experiment (Figure 3A). Sorted cells were not activated
when stored in EDTA tubes for up to 7 days (Figure 3B). In
contrast, an increase of the perturbation score was notable
when CD14+ cells were stored at room temperature
(RT) for longer than 4 hours, indicating activation of
transcription of stress response genes (Figure 3C). In
addition, the expression of 419 of 503 cell stress genes
(83%) was significantly affected after 4 hours storage at
RT (p-value < 0.05, absolute fold change > 1.5, data not
shown). In contrast, storage of CD14+ cells in EDTA at
4°C did not lead to gene expression changes during the
observation period of 7 days (Additional file 1: Figure S2).
None of the 503 selected cell stress genes showed statisti-
cally significant changes in expression levels between 0 days
and 7 days of storage (data not shown).
Enrichment of cell types by MACS cell separation
Blood samples and corresponding sorted cells from a subset
of donors (10 females, 13 males) were stored at 4°C
until analysis within 6 hours after venipuncture on a
MACSQuant Flow Cytometer (Miltenyi Biotec GmbH).
The purity of the sorted cells was within the specifications
of the vendor (Additional file 1: Table S3).
Gene expression analysis was applied to estimate the
enrichment of cells after cell sorting. As exemplified for
CD45+ cells in Figure 4, the normalized signal intensities
of the cell marker gene, in this case protein tyrosine phos-
phatase, receptor type C (PTPRC, CD45) did not change.
In contrast, the expression levels for other genes, typically
expressed in platelets, were strongly decreased in CD45+
cell preparations compared to whole blood. The repro-
ducibility of the procedure we applied is illustrated in
Figure 4A. The signal intensities of both the CD45 probeand the probe for hemoglobin delta (HBD) were consist-
ent within independent preparations from five individual
donors. To estimate the enrichment of CD45+ cells after
MACS Cell Separation, we analyzed the significance of
differences in signal intensities between CD45+ samples
and whole blood samples by ANOVA. From the genes with
the lowest p-value and highest absolute fold change, exem-
plary genes with platelet-specific expression were selected:
hemoglobin delta (HBD), hemoglobin beta (HBB), aminole-
vulinate, delta-, synthase 2 (ALAS2), erythrocyte membrane
protein 4.2 (EPB42), and glycophorin B (GYPB). All these
genes had higher expression values in whole blood than in
CD45+ cells (Figure 4B). To calculate the enrichment of
CD45+ cells after MACS Cell Sorting, the mean signal
intensity of the five platelet specific genes was calculated
for each sample. The ratio of group mean values and the
mean signal intensity of the CD45 probe (5788_at) indi-
cated an enrichment of CD45+ cells of 99%. The data imply
good coherence of cell population purity data calculated on
the transcript level with those measured by flow cytometry,
despite the application of different protocols.
Gene expression analysis of isolated cell types
Gene expression data from isolated cell types can be used
to address questions of basic biological relevance and for
pharmacological research or biomarker development.
Samples from eight isolated cell types and whole blood
(total number of samples N = 54) were subjected to gene
expression analyses. Principal component analysis (PCA)
is a computational data dimension reduction method and
was applied to visualize the relative similarities of samples
of different cell types and replicate groups. As shown in
Figure 5A, differences in gene expression lead to a segre-
gation of cell types and a clustering of samples by cell type
when the data from all genes were used. As expected, T
cell populations, i.e. CD3+, CD4+, and CD8+ cells formed
a T cell cluster but maintained their individual subtype
identity within this cluster. CD56+ natural killer cells, are
located nearest to the CD3+, CD4+, CD8+ T cell cluster.
Other cell types are separate from the T cell cluster and
whole blood cells. Similarly, hierarchical cluster analysis
with all genes reveals the close relationship of CD56+ cells
to the T cell group, consisting of CD3+, CD4+, and CD8+
cells (Figure 5B). As in the PCA, the closeness of the repli-
cates for a particular cell type is indicative of the good re-
producibility of the experiment.
To test whether the present dataset can be used for the
identification of genes with restricted expression signatures,
signal intensity data was subjected to stringent filtering
schemes. Expression in one cell type and not in the others
was defined as a signal intensity ≥200 in at least all but one
replicates of one cell type, and ≤100 in at least all but one
of the other samples (except whole blood). The cutoff of
100 was set as upper background range level. CD19+
Figure 4 Visualization of the enrichment of CD45+ cells. (A) Expression profiles of CD45 and Hemoglobin delta from five donors. Expression
levels indicate a 99% positive selection rate of CD45+ cells compared to blood, and a 97% enrichment compared to PBMC fractions. (B) The
expression levels of platelet-expressed transcripts are markedly reduced in CD45+ samples, indicating an enrichment of CD45+ cells. Expression
level reduction of genes expressed in blood but not in purified CD45+ cells indicate a 97% enrichment of CD45+. Mean values per group and
the standard error of mean are shown.
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followed by CD15+ (n = 59) and CD14+ (n = 33). No
genes were identified whose expression was restricted to
CD3+, CD4+ or CD8+ cells. When all three groups were
combined in the filter approach, high expression levels
were found for T cell receptor alpha variable 17
(TRAV17) in the three T cell subtypes. Some of the
data are depicted in Figure 6. The gene expression database
BioGPS (http://www.BioGPS.org/) and the software
Genevestigator (http://www.Genevestigator.com) served
as platforms to obtain third-party gene expression infor-
mation. Besides other functionalities, the BioGPS project
provides a reference gene expression atlas for a variety
of species, organs and isolated cell types [33]. As
shown in Figure 6, the trend towards specific expression of
C10orf11 in CD14+ cells was confirmed in BiogGPS and
Genevestigator. The gene CD19 was expressed exclusively
in CD19+ B lymphocytes. This was confirmed in the other
databases. Also high expression of MLC1 (megalencephalic
leukoencephalopathy with subcortical cysts 1), a gene withso far unknown gene function, was detected in CD56+
cells. There were no data available for T cell receptor alpha
variable 17 (TRAV17), a gene with expression limited to
CD3+, CD4+, and CD8+ T cells in our dataset. No data
were available for CD15+, CD3+, or blood-born CD45+
cells in the public databases.
Discussion
Despite methodological improvements in the develop-
ment of qualified, clinically relevant genomics biomarkers
with non- or minimally invasive technologies [34-36], the
path from discovery and validation, to regulatory approval,
acceptance, and clinical application remains a challenge
[37-39]. The analysis of genomics data of blood samples
is demanding, due to various potentially confounding
factors which need to be taken into account during the
analytical procedure, including i) relative blood cell-
type composition, ii) variation in cell-type gene expres-
sion signatures, iii) abundance of globin mRNA which
interferes with microarray signal intensities, and iv)
Figure 5 Reproducibility and integrity of cell type preparations. (A) Processed gene expression data of 8 separated cell types and of whole
blood was visualized in a dimension reduction method, principal component analysis (PCA). Signal intensities from all 18898 probes separate cell
types lead to a separation of cell types. T-cells (CD3+, CD4+ and CD8+) form one cluster which separates well from the B-cells (CD14+, CD15+,
CD19+, CD45+, CD56+) or full blood. Each sphere represents a single sample. The x- and the y-axis (principal components 1 and 2, respectively)
are labeled. The z-axis is not labled for graphical reasons. (B) Unsupervised hierarchical cluster analysis, same samples and gene list as in (A). Cluster
was generated with Euclidean distance and Ward’s method. Only sample dendrogram is shown. CD3+, CD4+, and CD8+ are grouped as “T cells”.
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name only some. The present project aimed to evaluate
whether gene expression analysis of cells separated dir-
ectly from whole blood by magnetic cell sorting (MACS
Technology) was feasible. After evaluating the effects of
several experimental conditions on RNA quality, and
yield, followed by gene expression analysis of eight sepa-
rated human blood cell populations, we concluded that
MACSCell Separation can be combined with gene expres-
sion profiling and is well suited for processing of clinical
trial samples. We found that EDTA-based anticoagulants
perform much better than formaldehyde-based additives
in terms of total RNA yield, integrity, and stability. The
EDTA blood collection tubes for molecular assays gave
the best results in terms of total RNA quality and quantity.
In our hands, one of the formaldehyde-based tube-type,
designed for stabilizing white blood cells for FACS analysis,
gave suboptimal total RNA quality scores independent of
the storage temperature and therefore we no longer evalu-
ated those collection tubes for our purpose.
It is known that nucleic acids from formalin-fixed,
paraffin-embedded (FFPE) tissues are usually significantly
degraded and chemically modified by formaldehyde causedby the fixation and embedding conditions [42]. There-
fore, nucleic acids isolated from FFPE samples are often
of a lower molecular weight than those obtained from
fresh or frozen samples. The other evaluated collection
tube, designed for stabilizing circulating tumor cells,
gave good quality total RNA when stored at 4°C for
3 days but the total RNA yields decreased and the tran-
scripts were not preserved as well as in the PAXgene Blood
RNA Tubes. These collection tubes with formaldehyde-
based additives were therefore not suitable for the purpose
of stabilizing the total RNA in this context.
RNA quality and yield were stable at a high level when
stored at 4°C throughout the observation period of up
to 7 days. Neither EDTA nor the addition of magnetic
beads activated the cells. Lyons et al. investigated the
effect of positive and negative selection by MACS Cell
Separation on the activation state of cells [23]. They
reported that positive selection did not activate the
leukocyte subsets, supporting the notion presented here,
that cells were not activated by storage or by MACS Cell
Separation. We determined the status of activation by a
series of experiments and the invention and application
of a so called perturbation score, which compresses
Figure 6 Cell type specific gene expression. Identification of cell type specific gene expression was performed by applying stringent filter on
the gene expression data (for details see Materials and Methods). Some of the results are shown. The databases BioGPS (www.BioGPS.org) and
the tool Genevestigator (www.genevestigator.com) were drawn upon to compare results of the present study with third party data. The present
dataset shows that cell separation provides known and novel information on gene expression. Expression patterns of C10orf11 (CD14+ cells),
CD19 (CD19+ cells), and MLC1 (CD56+ cells) was largely confirmed. No information was available for CD15+ cells in the external databases, and
there was no information on TRAV17, which was highly expressed in T cell subtypes.
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gene-groups into a single value. An unchanging perturb-
ation score indicated lack of activation. The concept of
gene scores to reflect severity of gene expression changes
is not new. Adopted by others, Famulski et al. have suc-
cessfully applied a gene score to clinical transplantationresearch and use it as molecular diagnostic tool [43-45].
Famulski’s gene score is based on fold change and is
thus dependent on reference gene expression data, for
example from control samples. In contrast, the per-
turbation score we applied in the present study is inde-
pendent of comparator data. Thus, individual samples
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gene groups.
Computational methods offer alternatives to physical
cell separation. However, changes in cell composition
and microenvironmental changes may represent obstacles
towards the investigation of gene expression changes within
a sample [46]. Several algorithms aiming to deconvolute
cell composition have been developed [47-49]. Some
algorithms rely on the a priori knowledge of either the
cell type composition in a sample or on pre-determined
gene expression profiles from isolated cell types [47,49].
Recently, the possibility to reconstruct cell type compos-
ition in complex tissues without prior knowledge of either
cell frequency or of pre-established cell type specific
gene expression signatures was investigated on simulated
data, awaiting further validation [50]. Other efforts aim to
deconvolute cell composition changes caused by micro-
environmental changes such as cell infiltration during pro-
gression of some diseases, or change of gene expression
profiles during disease treatment. Further advances in this
area, including validation, using data derived from clinical
samples, will be highly welcome. Physical cell separation
has limitations of its own. MACS Cell Separation can only
be performed on cells in suspension, and only by employ-
ing predefined cell surface markers or marker combina-
tions, excluding the discovery of new cell populations in a
sample. However, due to the high technical reproducibility
and robustness, MACS Cell Separation coupled to tran-
scriptomics presents a valuable platform for routine inves-
tigations in clinical trials.
Conclusions
Here we outline a workflow for magnetic bead-based,
delayed cell sorting of CD3+ T-lymphocytes, CD4+ helper
T-cells, CD8+ cytotoxic T-cells, CD14+ monocytes, CD15+
granulocytes, CD19+ B-lymphocytes, CD45+ leukocytes,
and CD56+ NK cells, designed for transcriptome analysis
of multi-center clinical trial samples. The observed cell-
stability at 4°C provides the potential to uncouple the blood
draw at the clinical site from MACS Cell Separation, e.g. at
a central laboratory. Cells were not activated by the MACS
process. This process facilitates the integration of cell sort-
ing directly from whole blood coupled to transcriptomics
in clinical trial protocols.
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